Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test
July 24, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New Findings Support Development of Racemic Tianeptine and (S)-Tianeptine (Estianeptine) as First-in-Class Oral Therapies in Alzheimer’s Disease and Other Psychiatric and Neurodegenerative Conditions...
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder
July 17, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company, today announced that the first participant has been enrolled in a...
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity
July 10, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve as a Novel Neuroendocrine...
Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies
July 06, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
“Examining the Working Definition for Long COVID” Included Presentations on Emerging Subgroups of Long COVID Patients Defined by Symptoms and Symptom Clusters “Toward a Common Research Agenda in...
Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products
July 03, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch®...
Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
June 26, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) are Indicated for the Treatment of Acute Migraine in Adults Strategic Acquisition Helps Build Tonix’s Commercial...
Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia
June 15, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Previously Disclosed Data Demonstrated that TNX-102 SL Achieved Statistically Significant Pain Reduction Over Placebo at Week 14 (Primary Endpoint, p=0.01) and Was Generally Safe and Well Tolerated ...
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress
June 07, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is Expected to Enter Phase 1 Clinical Development in Third Quarter 2023 CHATHAM, N.J,...
Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology Meeting
June 05, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tianeptine’s Mechanism of Restoring Neuroplasticity and Neurogenesis by Dual PPAR-β/δ and PPAR-γ Agonism Supports Development as a First-in-Class Oral Therapy for Psychiatric and Neurodegenerative...
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress
May 31, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an upcoming...